Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | FOS | P01100 | 1/20 | 0.41 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | DHODH | Q02127 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1015210 | 0.83 | KDM4E (0.38) | TSHRKDM4EALDH1A1LMNAGLA | |
| SCHEMBL3821041 | 0.79 | CSNK1D (0.46) | CSNK1DTSHRFOSJUNNFKB1 | |
| SCHEMBL23143266 | 0.78 | ELANE (0.42) | CSNK1DTSHRKDM4EALDH1A1MEN1 | |
| SCHEMBL30753543 | 0.78 | ELANE (0.42) | CSNK1DTSHRKDM4EALDH1A1MEN1 | |
| SCHEMBL3825413 | 0.78 | FOS (0.56) | CSNK1DTSHRFOSJUNNFKB1 | |
| SCHEMBL29906642 | 0.78 | TSHR (0.48) | TSHRKDM4EHSD17B10ALDH1A1MEN1 | |
| SCHEMBL1669584 | 0.78 | TSHR (0.48) | TSHRKDM4EHSD17B10ALDH1A1MEN1 | |
| SCHEMBL19627329 | 0.77 | CSNK1D (0.45) | CSNK1DFOSJUNNFKB1NFKB2 | |
| SCHEMBL23094518 | 0.77 | HSP90AA1 (0.59) | CSNK1DFOSJUNNFKB1NFKB2 | |
| SCHEMBL2327456 | 0.76 | TSHR (0.47) | TSHRKDM4EHSD17B10ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562306-B1 | METALLOENZYME INHIBITOR COMPOUNDS | JI XING PHARMACEUTICALS HONG KONG LTD (HK) | 2025-02-26 | — | — | EP | disclosed |
| US-11919883-B2 | Metalloenzyme inhibitor compounds | JI XING PHARMACEUTICALS HONG KONG LIMITED (HK) | 2024-03-05 | — | — | US | disclosed |
| US-20220009907-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2022-01-13 | — | — | US | disclosed |
| US-11136309-B2 | Metalloenzyme inhibitor compounds | PHASEBIO PHARMACEUTICALS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136309-B2 | Metalloenzyme inhibitor compounds | PHASEBIO PHARMACEUTICALS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200392112-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2020-12-17 | — | — | US | disclosed |
| US-20200392112-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2020-12-17 | — | — | US | disclosed |
| EP-3562306-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Selenity Therapeutics (Bermuda), Ltd. (BM) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018125799-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-07-05 | — | — | WO | disclosed |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
| WO-2018125799-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392112-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | CSNK1D 4037/4885TSHR 2240/4885FOS 4171/4885 |
| US-20220009907-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | CSNK1D 4037/4885TSHR 2240/4885FOS 4171/4885 |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | CSNK1D 4037/4885TSHR 2240/4885FOS 4171/4885 |
| US-11136309-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | CSNK1D 4037/4885TSHR 2240/4885FOS 4171/4885 |
| US-11919883-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | CSNK1D 4037/4885TSHR 2240/4885FOS 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.